Prostatype gives you a more accurate answer

Determining the prognosis for prostate cancer is like trying to put a puzzle together without all the pieces. Experienced doctors can get very far when it comes to giving the right diagnosis and prognosis, but in many cases it is difficult to determine with certainty how dangerous a cancer is and which possible treatments are best.

Oftentimes treatment is not necessary at all, and it’s sufficient with regular healthcare visits/check ups to ensure the cancer hasn’t developed in a way that would make treatment necessary. Some patients are unnecessarily operated, and in a number of cases aggressive prostate cancer which should be treated is missed.

Prostatype gives new prerequisites for reaching a clearer answer. Through gene analysis, the patient and doctor receive a measure indicating how aggressive or non-aggressive the cancer is. It provides a better basis when faced with the often difficult treatment decision.

Prostatype provides the patient and doctor with supplementary information prior to making a decision on whether or not treatment is necessary.

Prostatype’s unique system takes the cancer’s genetic fingerprint by measuring information from cancer stem cell genes in the tissue sample (the biopsy) which has already been taken in connection with the diagnosis. This is combined with other information from the diagnosis (PSA test, Gleason score, etc.), and a so called P-score is calculated. A P-score provides a measure of how aggressive or non-aggressive the cancer is, which eases the choice of optimal treatment.

Prostatype gives a value (P-score) of how aggressive the cancer is..

The result is an important piece of the puzzle and a valuable basis for doctor and patient in the conversation on how to proceed.

Background
Prostatype was developed by a research group from The Karolinska Institute and is manufactured and sold by Prostatype Genomics.